Taiho Oncology Inc. and Servier jointly announced the clinical data from the pivotal phase III trial evaluating Lonsurf (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pretreated metastatic gastric/gastroesophageal junction cancers who have progressed or are intolerant to previous lines of therapy.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
